2,2-dimethyl-4-<(4-tetradecylphenoxy)methyl>-1,3-dioxolane | 90857-77-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,2-dimethyl-4-<(4-tetradecylphenoxy)methyl>-1,3-dioxolane
• 英文别名: 2,2-Dimethyl-4-[(4-tetradecylphenoxy)methyl]-1,3-dioxolane
• CAS: 90857-77-5
• 化学式: C₂₆H₄₄O₃
• 分子量: 404.634
• InChiKey: ZTYNAUGQVHPVFJ-UHFFFAOYSA-N

物化性质

• 沸点：
  489.6±25.0 °C(Predicted)
• 密度：
  0.941±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  9.4
• 重原子数：
  29
• 可旋转键数：
  16
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,2-dimethyl-4-<(4-tetradecylphenoxy)methyl>-1,3-dioxolane 在 吡啶 、 盐酸 、 silicic acid-boric acid 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 Petroleum ether 为溶剂， 反应 99.0h， 生成 1-hydroxy-3-(3-tetradecylphenoxy)propan-2-yl acetate
  参考文献：
  名称：

  Analogs of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain

  摘要：

  Analogues of platelet activating factor (PAF) in which the ether oxygen has been removed (6) and in which the alkoxy chain at C1 has been replaced with a o-, p-, or m-alkylphenoxy group (30, 31, and 35, respectively) have been prepared. Compound 6 shows reduced platelet aggregation and hypotensive activity in comparison with C16 and C18 PAF. The results obtained for compounds 30, 31, and 35 indicate that the hypotensive and platelet aggregating responses are sensitive to structural modification of the ether chain. The ortho analogue 30 shows no platelet aggregating activity and only a weak hypotensive response. The para analogue 31 exhibits a moderate decrease in activity in both assays. The meta analogue 35 is the most active of the three.

  DOI：

  10.1021/jm00375a016
• 作为产物：
  描述：

  丙酮缩甘油 在 sodium hydride 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 30.0h， 生成 2,2-dimethyl-4-<(4-tetradecylphenoxy)methyl>-1,3-dioxolane
  参考文献：
  名称：

  Analogs of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain

  摘要：

  Analogues of platelet activating factor (PAF) in which the ether oxygen has been removed (6) and in which the alkoxy chain at C1 has been replaced with a o-, p-, or m-alkylphenoxy group (30, 31, and 35, respectively) have been prepared. Compound 6 shows reduced platelet aggregation and hypotensive activity in comparison with C16 and C18 PAF. The results obtained for compounds 30, 31, and 35 indicate that the hypotensive and platelet aggregating responses are sensitive to structural modification of the ether chain. The ortho analogue 30 shows no platelet aggregating activity and only a weak hypotensive response. The para analogue 31 exhibits a moderate decrease in activity in both assays. The meta analogue 35 is the most active of the three.

  DOI：

  10.1021/jm00375a016

文献信息

• Phosphocholine derivatives having antihypertensive action
  申请人：American Cyanamid Company

  公开号：US04640913A1

  公开（公告）日：1987-02-03

  Phosphocholine derivatives and compositions are described which are useful as hypotensive agents and in the treatment of hypertension in warm-blooded animals.

  磷酸胆碱衍生物和组合物被描述为在温血动物中作为降压剂和治疗高血压的有用药物。
• Analogs of platelet activating factor. 6. Mono- and bis-aryl phosphate antagonists of platelet activating factor
  作者：A. Wissner、M. L. Carroll、K. E. Green、S. S. Kerwar、W. C. Pickett、R. E. Schaub、L. W. Torley、S. Wrenn、C. A. Kohler

  DOI：10.1021/jm00087a023

  日期：1992.5

  A series of aryl phosphoglyceride (3, 19-6 1) and bis-aryl phosphate (67-135) antagonists of platelet activating factor (PAF) were prepared. A group of four bifunctional phosphorus reagents (5a-c and 7) were developed that allowed the preparation of these aryl phosphates in which the position of aromatic substitution can be varied. These compounds were examined for their ability to inhibit PAF-induced platelet aggregation of rabbit platelets. Selected compounds were also evaluated for their ability to displace [H-3]PAF from its receptor on rabbit platelets. These in vitro data were compared to similar data obtained for a number of known PAF antagonists. The compounds were evaluated in vivo, in both the mouse and rabbit, for their ability to prevent death induced by a lethal challenge of PAF. The relationships between the biological activity and the nature, lipophilicity, and position of substituents of the aromatic rings were studied. Compound 105 (CL 184005) has been selected to undergo further development as a potential therapeutic agent for the treatment of septic shock in man.
• US4640913A
  申请人：——

  公开号：US4640913A

  公开（公告）日：1987-02-03
• Analogs of platelet activating factor (PAF). 1. Some modifications of the alkoxy chain
  作者：A. Wissner、P. E. Sum、R. E. Schaub、C. A. Kohler、B. M. Goldstein

  DOI：10.1021/jm00375a016

  日期：1984.9

  Analogues of platelet activating factor (PAF) in which the ether oxygen has been removed (6) and in which the alkoxy chain at C1 has been replaced with a o-, p-, or m-alkylphenoxy group (30, 31, and 35, respectively) have been prepared. Compound 6 shows reduced platelet aggregation and hypotensive activity in comparison with C16 and C18 PAF. The results obtained for compounds 30, 31, and 35 indicate that the hypotensive and platelet aggregating responses are sensitive to structural modification of the ether chain. The ortho analogue 30 shows no platelet aggregating activity and only a weak hypotensive response. The para analogue 31 exhibits a moderate decrease in activity in both assays. The meta analogue 35 is the most active of the three.